Bedaquiline in the treatment of multidrug- and extensively drugresistant tuberculosis

European Respiratory Journal

Volumn 47, Issue 2, 2016, Pages 564-574

  Pym, Alexander S ^a,j   Diacon, Andreas H ^b   Tang, Shen Jie ^c   Conradie, Francesca ^d   Danilovits, Manfred ^e   Chuchottaworn, Charoen ^f   Vasilyeva, Irina ^g   Andries, Koen ^h   Bakare, Nyasha ⁱ   De Marez, Tine ⁱ   Haxaire Theeuwes, Myriam ^h   Lounis, Nacer ^h   Meyvisch, Paul ^h   Van Baelen, Ben ^h   Van Heeswijk, Rolf P G ^h   Dannemann, Brian ⁱ   Chen, Xiaohong ^k   Chu, Naihui ^k   De Los Rios, Jorge ^k   Diaz, Dina ^k   Erokhin, Vladislav ^k   Flores, Victor ^k   Hwang, Sung Chul ^k   Iberico, Carlos ^k   Kazennyi, Boris ^k   Kim, Young Sam ^k   Kurve, Anu ^k   Kuzhko, Mykhaylo ^k   Jung Kwon, O ^k   Leimane, Vaira ^k   Lyepshina, Svetlana ^k   Maryandyshev, Andrey ^k   Melnyk, Vasiliy ^k   Narasimooloo, Ronelle ^k   Qiu, Lihua ^k   Ortaköylü, Gönenç ^k   Ozkara, Seref ^k   Reano, Rafael ^k   Shim, Tae Sun ^k   Chavez, Eduardo Ticona ^k   Wiwatworapan, Tawatchai ^k   Zhang, Xia ^k   more..

^a AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e TARTU UNIVERSITY HOSPITAL   (Estonia)

^f MINISTRY OF PUBLIC HEALTH   (Thailand)

^g CENTRAL TUBERCULOSIS RESEARCH INSTITUTE   (Russian Federation)

^h JANSSEN RESEARCH FOUNDATION   (Belgium)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^j UNIVERSITY OF KWAZULU NATAL   (South Africa)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BEDAQUILINE; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; TERIZIDONE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ACUTE PANCREATITIS; ADULT; AGED; ARTHRALGIA; ARTICLE; ASIA; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EASTERN EUROPE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; OPEN STUDY; PERU; PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; SKIN DISEASE; SOUTH AFRICA; TREATMENT DURATION; VOMITING; ADOLESCENT; CLINICAL TRIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MIDDLE AGED; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84958073475     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00724-2015     Document Type: Article

References (35)

1. World Health Organization. Global Tuberculosis Report 2014. http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809-eng.pdf?ua=1 Date last accessed: May 5, 2015.
2. Shah NS, Wright A, Bai G-H, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-387.
3. Banerjee R, Allen J, Westenhouse J, et al. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin Infect Dis 2008; 47: 450-457.
4. Ahuja SD, Ashkin D, Avendano XM, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
5. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375: 1798-1807.
6. O'Donnell MR, Padayatchi N, Kvasnovsky C, et al. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis 2013; 19: 416-424.
7. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
8. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
9. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-227.
10. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance (WHO/HTM/TB/2013.6). http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482-eng.pdf Date last accessed: May 5, 2015.
11. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
12. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.
13. Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188-194.
14. Udwadia ZF, Amale RA, Mullerpattan JB. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India. Int J Tuberc Lung Dis 2014; 18: 1315-1318.
15. Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015; 19: 979-985.
16. Diacon AH, Pym A, Grobusch MP, et al. The diarylquinoline bedaquiline for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
17. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-3276.
18. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008 (WHO/HTM/TB/2008.402). http://whqlibdoc.who.int/publications/2008/9789241547581-eng.pdf Date last accessed: May 5, 2015.
19. National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases (DMID) adult toxicity table, November 2007. www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidadulttox.pdf Date last accessed: May 5, 2015.
20. Medical Dictionary for Regulatory Activities (MedDRA). Standardised MedDRA queries. http://www.meddra.org/standardised-meddra-queries Date last accessed: May 5, 2015.
21. World Health Organization. Treatment of tuberculosis: guidelines. 4th Edn (WHO/HTM/TB/2009.420). www.aidsdatahub.org/dmdocuments/Treatment-of-TB-Guidelines.pdf Date last accessed: May 5, 2015.
22. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010; 14: 275-281.
23. Sagwa E, Mantel-Teeuwisse AK, Ruswa N, et al. The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia. South Med Rev 2012; 5: 6-13.
24. Shen X, Yuan Z, Mei J, et al. Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law. Drug Saf 2014; 37: 43-51.
25. Andries K, Villellas C, Coeck N, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014; 9: e102135.
26. Keshavjee S, Gelmanova IY, Shin SS, et al. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. Int J Tuberc Lung Dis 2012; 16: 596-603.
27. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014; 383: 1230-1239.
28. Falzon D, Mirzayev F, Wares F, et al. Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J 2015; 45: 150-160.
29. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979-2981.
30. Gupta S, Cohen KA, Winglee K, et al. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 574-576.
31. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
32. Aung KJ, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-1187.
33. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
34. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
35. Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.